Rivaroxaban

"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Descriptor ID	D000069552
MeSH Number(s)	D02.886.778.727 D03.383.533.640.713 D03.383.903.727
Concept/Terms	Rivaroxaban Rivaroxaban 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide Xarelto Xarelto BAY 59-7939 BAY 59-7939 BAY 59 7939 BAY 597939

Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Sulfur Compounds [D02.886]
Thiophenes [D02.886.778]
Rivaroxaban [D02.886.778.727]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Oxazines [D03.383.533]
Morpholines [D03.383.533.640]
Rivaroxaban [D03.383.533.640.713]
Thiophenes [D03.383.903]
Rivaroxaban [D03.383.903.727]

Below are MeSH descriptors whose meaning is related to "Rivaroxaban".

Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.

Bar chart showing 25 publications over 10 distinct years, with a maximum of 7 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2013	0	1	1
2014	0	7	7
2015	1	0	1
2016	0	4	4
2017	1	0	1
2018	0	1	1
2019	1	0	1
2020	0	3	3
2021	1	4	5
2022	0	1	1

Below are the most recent publications written about "Rivaroxaban" by people in Profiles.

Mar PL, Gopinathannair R, Gengler BE, Chung MK, Perez A, Dukes J, Ezekowitz MD, Lakkireddy D, Lip GYH, Miletello M, Noseworthy PA, Reiffel J, Tisdale JE, Olshansky B. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol. 2022 06; 15(6):e007956.

View in: PubMed
Mamas MA, Batson S, Pollock KG, Grundy S, Matthew A, Chapman C, Manuel JA, Farooqui U, Mitchell SA. Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation. Am J Cardiol. 2022 03 01; 166:58-64.

View in: PubMed
Cappato R, Ezekowitz MD, Hohnloser SH, Meng IL, Wosnitza M, Camm AAJ. Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial. Europace. 2021 10 09; 23(10):1539-1547.

View in: PubMed
Albers GW, Bernstein R, Brachmann J, Camm AJ, Fromm P, Goto S, Granger CB, Hohnloser SH, Hylek E, Krieger D, Passman R, Pines JM, Kowey P. Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke. 2021 08; 52(8):2715-2722.

View in: PubMed
Chaudhry UA, Ezekowitz MD, Gracely EJ, George WT, Wolfe CM, Harper G, Harper GR. Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged =80 years With Atrial Fibrillation. Am J Cardiol. 2021 08 01; 152:69-77.

View in: PubMed
Turakhia M, Sundaram V, Smith SN, Ding V, Michael Ho P, Kowey PR, Piccini JP, Foody J, Birmingham MC, Ianus J, Rajmane A, Mahaffey KW. Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. Am Heart J. 2021 07; 237:68-78.

View in: PubMed
Abdullah HM, Ullah W, Jafar MS, van Zyl M, Saeed R, Alam M, Alraies MC, Fischman DL. Safety and Efficacy of Apixaban, Rivaroxaban, and Warfarin in End-Stage Renal Disease With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiovasc Revasc Med. 2021 09; 30:26-32.

View in: PubMed
Sedhom R, Abdelmaseeh P, Megaly M, Asinger R. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review. Am J Med. 2020 11; 133(11):1266-1273.e6.

View in: PubMed
Barkoudah E, Piazza G, Hecht TEH, Grant P, Deitelzweig S, Fang MC, Fanikos J, Kao CK, Barnes GD, Chen T, Ramishvili T, Schnipper JL, Goldstein JN, Ruff CT, Kaatz S, Schwartz A, Connors JM, Goldhaber SZ. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. Am J Med. 2020 05; 133 Suppl 1:1-27.

View in: PubMed
Ablefoni K, Buchholz A, Ueberham L, Hilbert S, Dagres N, Husser D, Hindricks G, Bollmann A. Initial rivaroxaban dosing in patients with atrial fibrillation. Clin Cardiol. 2019 Oct; 42(10):873-880.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement